Kornimate/medical-research-clean huggingface dataset:
healthy homes/healthy families

Conditions: Chronic Diseases

Summary: the purpose of the study is to learn how to make homes more supportive of healthy eating and physical activity. as part of the study, participants will be randomly assigned to one of two groups. one group will receive materials with information on healthy eating and physical activity. the materials will be mailed 3 times over a 5 month period. the other group will work with a coach to make their homes more supportive of healthy eating and physical activity. working with a coach involves 3 home visits and 4 coaching telephone calls over a 5 month period. this group will also receive materials by mail 4 different times. all participants will be asked to complete 7 telephone interviews over a 1 year period. participants will also be asked to wear an accelerometer, a small portable device that tracks movement from physical activity, for 7 days at 2 different points in the study.


Eligibility criteria:
inclusion criteria: * female * 35-65 years old * bmi greater than or equal to 25 * speak english * must live with at least one other person * live within 30 miles of 1 of 9 clinics referring patients in the study * must have no contraindications for physical activity * must have no contraindications for participating in a medically unsupervised study exclusion criteria: * 1 person per household
clinic study of 18f-al-nota-matbbn in cancer diagnostics

Conditions: Breast Neoplasms; Prostatic Neoplasms

Summary: the purpose of this study is to determine whether 18f-al-nota-matbbn is safety and effective for cancer diagnosis.

observe radiation dose to healthy volunteers and patients; the correlation between integrin level and tumor/metastases uptake.

Eligibility criteria:
inclusion criteria: 1. volunteers or patients with age more than 18 yeas; 2. the patients have been diagnosed with cancer or suspected with cancer; 3. it must fulfill the ethical requirements and subjects have signed an informed consent. exclusion criteria: 1. pregnancy or nursing mothers; 2. having drugs or alcohol dependence; 3. hypersensitive to the active or inactive ingredients of the study drug; 4. having attended other drug clinical trials within three months; 5. cardiac functional insufficiency; 6. hepatic and renal function insufficiency; 7. hypertensive patients with serious complications; 8. endangering the safety of life.

Keywords: breast neoplasms,prostatic neoplasms
terbutaline concentrations in blood and urine

Conditions: Asthma

Summary: the purpose of this study is to assess the blood and urine concentrations of terbutaline and to evaluate the difference between inhaled and oral terbutaline in order to distinguish treatment with terbutaline from doping with terbutaline in a doping control.

to investigate the serum and urine concentrations of terbutaline and evaluate the difference between inhaled terbutaline (2 mg) and oral terbutaline (10 mg) in order to distinguish doping with terbutaline from anti-asthmatic treatment with terbutaline. to investigate the above mentioned in three groups: healthy men, male asthmatic subjects and male elite athletes with asthma.

Eligibility criteria:
inclusion criteria: * physician-diagnosed asthma with positive reversibility or challenge test. * informed consent. * age between 18 - 45 years. * sex: male. * asthma classified as mild to moderate according to gina guidelines. * used beta-2-agonist in minimum 12 months. exclusion criteria: * smokers or ex-smokers with a smoking history of 10 pack years or more. * respiratory tract infections within the last 2 weeks prior to visit 1 and 2. * subjects with other chronic diseases than asthma and allergy. * allergy towards the study medicine. * use of beta-2-agonist 6 days prior to study day.

Keywords: asthma doping beta agonist terbutaline pharmacokinetics
pancreatic stone protein (psp) in pregnant women

Conditions: Pregnancy; HELLP Syndrome; Preterm Premature Rupture of Fetal Membranes; Preeclampsia

Summary: this prospective, single centred cohort study evaluates the physiological course of the potentially novel biomarker psp in pregnant women as well as its predictive role in the development of inflammatory complications during pregnancy.

pregnant women feature a complex immunological condition caused by pregnancy itself and hence women present with an increased susceptibility to some infectious and non-infectious inflammatory diseases. specifically regulated mechanisms have been described occurring in normal whereas lacking in pathological pregnancies in both the native and adaptive immune system in animal models and humans. however, clinically relevant biomarker associated with preterm premature rupture of membranes (pprom), amniotic infection syndrome (ais) as well as pregnancy associated complications such as preeclampsia and hemolysis, elevated liver enzymes, and low platelets (hellp) syndrome have their limitations. pancreatic stone protein (psp), originally obtained from human pancreatic stones from patients operated for chronic calcifying pancreatitis, has been studied in several gastrointestinal pathologies. the aim of this study is to evaluate the physiological course of the potentially novel biomarker psp in pregnant women as well as to assess its predictive role in the development of inflammatory complications during pregnancy.

Eligibility criteria:
inclusion criteria: * age \> 18 years * healthy women with single pregnancy * women with pprom, ais, preeclampsia, or hellp syndrome * patients able to provide informed consent exclusion criteria: * viral (hepatitis b virus, hepatitis c virus, human immunodeficiency virus) or confirmed bacterial infections

Keywords: pancreatic stone protein (psp) premature rupture of membranes (pprom) amniotic infection syndrome (ais) hemolysis, elevated liver enzymes, and low platelets (hellp) preeclampsia pregnancy
dipole density mapping of typical atrial flutter

Conditions: Atrial Flutter

Summary: study to determine the feasibility of the acutus medical system in obtaining data to create dipole density maps of electrical activation in the right atrium in patients with typical atrial flutter.


Eligibility criteria:
inclusion criteria: 1. be aged 18 to 75 years 2. be scheduled for ablation of typical atrial flutter (cavotricuspid isthmus dependent) 3. be able and willing to give informed consent exclusion criteria: 1. have any of the following: 1.1 patients with implanted prosthetic, artificial, or repaired cardiac valves in the chamber being mapped. 1.2 patients with permanent pacemaker or icd leads in the chamber being mapped. 1.3patients with hypercoagulopathy or an inability to tolerate anticoagulation therapy during an electrophysiology procedure. 2. require treatment in the left atrium and/or a require a transseptal puncture to access the left atrium during the index procedure 3. have had a myocardial infarction within the prior two months 4. have had cardiac surgery within the prior three months 5. have an intracardiac thrombus 6. have clinically significant tricuspid valve regurgitation or stenosis 7. have had any cerebral ischemic event (including transient ischemic attacks) in the prior six months 8. be pregnant or nursing 9. be currently enrolled in any other clinical investigation
explore the clinical value of 68ga-dotanoc pet/ct and 18f-fdg pet/ct in neuroendocrine neoplasms

Conditions: Neuroendocrine Tumors

Summary: 68ga-dotanoc and 18f-fdg pet/ct have important values in the staging and clinical treatment of neuroendocrine tumors. retrospective studies suggest that the positivite rates and suvmax of dual imaging associated with pathological findings and prognosis. the study was designed to confirm thet clinical values of dual imagings for neuroendocrine tumors.


Eligibility criteria:
inclusion criteria: 1. sign written informed consent form 2. age ≥ 18 years 3. pathologically confirmed neuroendocrine, ki67\>=10%; 4. ecog 0-1; 5. no prior antitumor treatment with chemotherapy targeting regimens for neuroendocrine carcimomas, no more than 2 systematic treatment for neuroendocrine tumors; 6. unresectable disease; 7. at least 1 measurable lesion (only 1 measurable lymph node lesion is excluded) (routine ct scan \>=20mm, spiral ct scan \>=10mm, no prior radiation to measurable lesions); 8. predicted survival \>=3 months; 9. negative serum or urine pregnant test within 7 days prior to randomization for child-bearing age women; 10. sexually active males or females willing to practice contraception during the study until 30 days after end of study. exclusion criteria: 1. in the process of antitumor therapy with effective response; 2. refuse to accept pet/ct; 3. pregnant or nursing, or sexually active males or females refuse to practice contraception during the study until 30 days after end of study; 4. person with no capacity (legally) or inappropriate to continue study treatment for ethics/medical reasons；

Keywords: positive rate suvmax relationship
anatomic and biomechanical investigation on acl: a cadaveric study

Conditions: Anterior Cruciate Ligament Rupture

Summary: the present study was aimed to investigate the kinematics differences between round-tunnel (rot) and flat-tunnel (flt) techniques and compare the influence to the anterior root of lateral meniscus (arlm ) in anterior cruciate ligament (acl) reconstruction when using hamstring graft.

nine matched pairs of fresh-frozen cadaveric knees were evaluated for the kinematics of intact, acl-sectioned, and either rot or flt reconstructed knees. the graft bundles for flt technique were separately tensioned. a 6 degrees of freedom robotic system was used to assess knee laxity: (1) 134-n anterior tibial load at 0°, 15°, 30°, 60°, and 90°of knee ﬂexion. (2) 10-nm of valgus torque followed by 5-nm of internal rotation torque simulates a pivot-shift test at 15°, 30°. (3) 5-nm internal and external rotation torques at 0°, 15°, 30°, 60°, and 90°. (4) 10-nm varus and valgus torques at 15°, 30°. coverage of acl tibial footprint and areas of arlm attachment before and after reaming were measured using three-dimensional isotropic mri scanning.

Eligibility criteria:
inclusion criteria: * intact knee with no previous injures exclusion criteria: * those with ligamentous injury or a limited range of motion
epanova in crohn's disease, study 1

Conditions: Crohn's Disease

Summary: the primary objective of this study is to assess the ability of epanovatm soft gelatin capsules at a total daily dose of 4g (4x 1g capsules) to maintain remission (crohn's disease activity index cdai \< 150) in cd patients in whom remission, stable for at least three months and no longer than one year, has been induced by corticosteroids, azathioprine/6-mp, methotrexate, 5-asa or antibiotics. secondary objectives are to assess the: efficacy of epanova versus placebo by crohn's disease activity index (cdai), investigator and subject global ratings, employment status and use of cd related medical visits in subjects with cd in remission safety and tolerability of epanova ability of epanova to maintain the quality of life of cd patients in remission


Eligibility criteria:
inclusion criteria: 1. male or female subject, age 17 or older; country-specific age limitations will be followed 2. diagnosis of crohn's disease confirmed by radiological studies or endoscopy or surgical pathology within 36 months prior to randomisation 3. in remission for at least 3 months, but no longer than 12 months; remission being defined as meeting both of the two conditions: (1) clinically in remission with a cdai of less than 150 and (2) off steroids and/or immunosuppressants for at least 3 months, if remission had been induced with such medications exclusion criteria: 1. intolerance of omega-3 fatty acids or known allergy to fish or fish products 2. ongoing cd therapy with: 5-asa compounds, steroids, immune modifiers, systemic antibiotics, tube feeding, defined formula diets or parenteral nutrition 3. in 3 months prior to randomisation received: systemic steroid therapy, azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, probiotic products or preparations containing fish oil 4. in 12 months prior to randomisation received: biologicals e.g. enbrel, infliximab, mycophenolate, tacrolimus, thalidomide, other immune modifiers and/or investigational products 5. chronic use of narcotics for pain control (opiates for diarrhoea are acceptable) 6. documented short bowel syndrome, ostomy 7. need for bowel surgery for cd, bowel obstruction or resection in past 3 months (a subject who had a bowel resection in the past must have had at least one relapse after the surgery) 8. malignancy and/or clinically significant impairment in cardiac, liver or renal function, cns, pulmonary, hematological, immunological, vascular and gastrointestinal disease in addition to cd 9. known alcoholism or drug abuse 10. any medical conditions which, in the investigator's opinion, may interfere with the evaluation of the trial medication 11. any of the following laboratory abnormalities: * white blood count \< 3 x 109/l * lymphocyte count \< 0.5 x 109/l * haemoglobin \< 80 g/l * platelet count \ 800 x 109/l * alt or ast \> 2.0 times the upper limit of normal * alkaline phosphatase \> 2.0 times the upper limit of normal * serum creatinine \> 1.5 times the upper limit of normal

Keywords: crohn's disease
use of cbt-i in individuals with a concussion

Conditions: Concussion, Mild

Summary: sleep disturbances have been shown to contribute to poorer recovery from a concussion. furthermore, sleep disturbances have been associated with more frequent and severe post-concussion symptoms including headache, vertigo, anxiety, depression, and decreased short term memory reducing quality of life and productivity at work or school. additionally, recent research indicates that individuals with a concussion who have poor sleep quality have increased levels of neurofilament light (nfl) and tau biomarkers indicating that there may still be axonal damage after weeks or months after the initial concussion injury. post-concussion symptoms have been associated with higher levels of these biomarkers and there has been a report of higher levels of nfl and tau years following a concussion event. cognitive behavioral therapy for insomnia (cbt-i) is an effective treatment for insomnia yet it remains unclear if this treatment method is effective in improving sleep outcomes, reducing concomitant post-concussion symptoms, and biomarkers of neural injury/risk in individuals post- concussion. the central hypothesis for this project is treating sleep disturbances will yield a clinically relevant reduction in concomitant post-concussion symptoms. the objective for the proposed study is to determine if cbt-i will reduce insomnia symptoms and improve concomitant post-concussion symptoms in individuals after concussion and if symptom improvements are maintained at 6-weeks and 12-weeks after cbt-i intervention.


Eligibility criteria:
inclusion criteria: * aged 18 to 64 years old * at least 4 weeks since concussion injury * self-report difficulty falling asleep, maintaining sleep, or waking up too early at least 3 nights per week since injury * score ≥10 on the insomnia severity index to indicate clinical insomnia. * score ≥25 on the mini-mental state examination (mmse) questionnaire exclusion criteria: * known untreated sleep disorder (such as sleep apnea, restless leg syndrome, circadian rhythm disorder, hypersomnia, parasomnias) * increased risk obstructive sleep apnea (stop bang score ≥3) * increased risk of restless leg syndrome on rls-diagnosis index * increased risk of circadian rhythm sleep-wake disorder (respond "yes" to all circadian rhythm questions). * increased risk of parasomnia (respond "yes" to all questions for night mere disorder or respond "yes" to all rem sleep arousal disorder: sleep walking questions, or responds " yes" to all rem sleep arousal disorder: sleep terrors questions, or respond "yes" to all rem sleep behavior disorder questions.) * active abuse or history (up to 2 years) of alcohol/ drug dependence as defined by the dsm-v criteria * severe mental illness such as schizophrenia or bipolar disorder * score of \> 29 on the beck depression inventory or indication of suicidality (response of "2" or "3"to item 9) * history of diagnosed nervous system disorder other than concussion (such as multiple sclerosis, parkinson's disease, stroke) * currently works nightshift
the value of memory b cells marker (cd27) and howell jelly bodies detrection in critically ill patients

Conditions: Sepsis

Summary: a total of ninety - five patients (54men and 41women) were included in the study. fifty-eight patients developed septic complication during icu stay (sepsis group). forty seven patients were critically ill without evidence of infectious organism (sirs group). at admission, patients data include clinical status; sofa score; central venous pressure; laboratory analysis and arterial blood gas analysis were measured. routine cultures were obtained. the attending physician evaluated the patients for sepsis, severe sepsis, or septic shock as long as their stay in icu. memory b cells and heinz bodies were monitored.

the patients staying in icu for more than 24 hours were enrolled in the study. patients received anti-inflammatory drugs or corticosteroids before admission, patients had immunosuppressive illness, patients had chronic organ failure; patients received massive blood transfusion; patients with radiation therapy and patients with previous organ transplantation were excluded from the study. at admission, patient's age, sex, weight and height were recorded. patients data that include the clinical status; sequential organ failure assessment (sofa) score; temperature; heart rate; respiratory rate; blood pressure; central venous pressure; laboratory analysis (complete blood count, blood urea nitrogen, blood sugar, serum sodium, potassium, calcium, aspartate aminotransferase, alanine aminotransferase, prothrombin time, albumin and crp) and arterial blood gas analysis were measured. routine cultures of suspected sites, blood and urine were obtained to determine the presence of infection. we attempted to maintain the patient hemoglobin level at 10-12g/dl and central venous pressure at 8-12 cmh2o. when needed, intravascular fluid replacement, blood products and inotropic or vasopressor agents were administered. each day the attending physician evaluated all the study patients for sepsis, severe sepsis, or septic shock as long as their stay in icu.

Eligibility criteria:
inclusion criteria: * critically ill patients with manifestation of sepsis or sirs exclusion criteria: * patients received anti-inflammatory drugs or corticosteroids before admission, who had immunosuppressive illness, who had chronic organ failure; who had received massive blood transfusion; those with radiation therapy, previous organ transplantation were excluded from the study.

Keywords: critically ill patient.
epcam-targeted surface-enhanced raman spectroscopy nanotags for rapid evaluation of surgical margins and sentinel lymph node metastasis status in breast cancers

Conditions: Sentinel Lymph Node; Breast Cancers; Metastases; Margin Assessment

Summary: for early breast cancer patients, breast-conserving surgery and sentinel lymph node biopsy have emerged as the cornerstone of precision oncology, harmonizing oncologic efficacy with the preservation of breast cosmetics and axillary function. however, conventional margin evaluation relies on subjective experience, leading to positive margin rates of 15%-50% additionally, sentinel lymph node biopsy faces inherent technical limitations, including prolonged procedural time and significant false-negative rates in detecting micro-metastases. to overcome these challenges, the investigators will introduce a stable "sandwich" epcam-targeted surface-enhanced raman spectroscopy (sers) detection system to provide rapid evaluation of surgical margins and sentinel lymph node (sln) metastasis status. in brief, a portion of resected tissue will be immediately homogenized by grinding, and the tissue homogenate will then be analyzed using this detection system to determine its histological characteristics. pathological confirmation will further validate the method. this approach aims to improve the accuracy and efficiency of intraoperative assessment of breast-conserving surgical margins and sln status, thereby effectively reducing local recurrence rates and complications.


Eligibility criteria:
inclusion criteria: * adult patients between 18-75 years of age * female * patients presenting with a breast cancer to be resectable on pre-operative assessment * good operative candidate * subject capable of giving informed consent and participating in the process of consent exclusion criteria: * patients unable to participate in the consent process * patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc * other conditions that the researcher considers inappropriate to participate in the study

Keywords: sentinel lymph node surface enhanced raman spectroscopy epcam breast cancers surgical margin
mindfulness-based social cognition training for psychosis (socialmind): a feasibility study

Conditions: Schizophrenia and Disorders With Psychotic Feature; Psychotic Episode

Summary: the current investigation has been designed to test the feasibility of a mindfulness-based social cognition training (socialmind) for people with a first episode of psychosis (ages-mind study, nct03309475). the intervention has been designed by professionals with both formal training and clinical experience in the field of mindfulness and third generation cognitive-behavioral therapies. main outcomes are recruitment rate, adverse events and treatment adherence, although therapy effects and adjustment to intervention manual are also explored.

social functioning is impaired among many patients with a first episode of psychosis, who also show a lower ability to recognize, understand and benefit from social stimuli (i.e., deficits in social cognition) than their pairs. both deficits underlie the general functional impairment found across non-affective psychotic syndromes. since currently available pharmacological strategies have not proven themselves effective in addressing this matter, new psychotherapeutic approaches should be developed. this research team developed a mindfulness-based social cognition group training (socialmind) designed for persons who have suffered a first episode of psychosis within five years prior to their enrollment in the study (ages-mind study, nct03309475). although there is enough evidence to support the lack of adverse events derived for mindfulness-based interventions specifically designed for psychotic patients (cramer et al., 2016), many clinicians express their concerns about the beneficial effects of these approaches. therefore, and in keeping with international health organisms such as united kingdom's national health service (nhs), this team have proposed a feasibility study. the main hypothesis is that the ages-mind study can be carried out in terms of achievement of recruitment rate, lack of adverse events and levels of treatment adherence. secondary hypothesis states that clinicians will adhere to socialmind manual. finally, a positive effect of the intervention is expected, both in participants' satisfaction and in some relevant variables, such as functional outcomes, clinical global impression and social cognition.

Eligibility criteria:
inclusion criteria: * 18-60 years old * diagnosis of psychotic disorder according to dsm-5 and history of more than five years of psychotic symptoms * cgi-sch equal or lower than four points ("moderately ill") * informed consent given exclusion criteria: * intellectual disability plus impaired global functioning prior to disorder onset * generalized development disorder * substance related disorders (except for nicotine) according to dsm-5

Keywords: schizophrenia mindfulness social cognition socialmind ages-mind